Market Place
Sourcing Support
Estrella Immunopharma Announces $8M Private Placement
05 Jan 2026 //
BUSINESSWIRE
Estrella Advances STARLIGHT-1 to Phase II After DSMB Review
04 Dec 2025 //
BUSINESSWIRE
Estrella Immunopharma Finishes Second Dose Cohort In STARLIGHT-1
03 Nov 2025 //
BUSINESSWIRE
Estrella Immunopharma Restores Nasdaq Listing Compliance
06 Oct 2025 //
BUSINESSWIRE
Estrella Adds Trial Site for Ph I/II in Non-Hodgkin`s Lymphoma
05 Jun 2025 //
BUSINESSWIRE
Estrella Immunopharma Announces $3.35M Private Placement
03 Jun 2025 //
BUSINESSWIRE
Estrella Immunopharma Starts Second Cohort in EB103 Trial
29 May 2025 //
BUSINESSWIRE
Estrella Gets Buy Rating, $14 Target From CB Capital
05 Mar 2025 //
BUSINESSWIRE
Estrella Immunopharma Gets Buy Rating, $16 Price Target From Boral
19 Feb 2025 //
BUSINESSWIRE
Estrella Immunopharma Achieves Complete Response In First Patient
27 Sep 2024 //
BUSINESSWIRE
Estrella Immunopharma Appoints Hong Zhang As Chairperson And Board Member
14 Aug 2024 //
BUSINESSWIRE
TradeUP Acquisition and Estrella Announce Completion of Business Combination
29 Sep 2023 //
PR NEWSWIRE
Estrella Announces FDA Clearance of IND Application for PhI/II Trial of EB103
08 Mar 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.